Skip to content
Menu

JP Morgan Maintains Overweight on Maze Therapeutics, Lowers Price Target to $51

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and lowers the price target from $53 to $51.

Read at benzinga.com